From Pipeline To Patient: How PIE Streamlines Biopharma And Payer Communication

Engaging in pre-approval information exchange (PIE) between biopharma companies and healthcare decision-makers (HCDMs) has become a crucial strategy for expediting product access and enabling informed formulary decisions. This proactive communication provides an opportunity to discuss pipeline products and indications before FDA approval, which can significantly speed up the P&T review process. It also helps with budget forecasting, allowing for a smoother integration of new therapies.

PIE is a chance to control your product’s narrative and prevent competitors from defining the conversation. The regulations around PIE are less restrictive than many people think; a wide range of product-related information can be shared as long as it is truthful and non-misleading. By taking a bidirectional, comprehensive approach, biopharma companies can build trust with payers, fill critical information gaps, and ultimately set the stage for successful post-approval communications. Discover more insights on the importance of PIE and how a strategic approach can benefit all stakeholders.